MNG435
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.506
- HEDGEHOG_SIGNALING+0.472
- MITOTIC_SPINDLE+0.423
- UV_RESPONSE_DN+0.404
- HYPOXIA+0.388
- TGF_BETA_SIGNALING+0.362
- ANDROGEN_RESPONSE+0.341
- PROTEIN_SECRETION+0.304
- WNT_BETA_CATENIN_SIGNALING+0.289
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.281
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.519
- MYC_TARGETS_V1-0.415
- MYC_TARGETS_V2-0.415
- DNA_REPAIR-0.331
- INTERFERON_ALPHA_RESPONSE-0.329
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.298
- ALLOGRAFT_REJECTION-0.222
- INTERFERON_GAMMA_RESPONSE-0.202
- ADIPOGENESIS-0.199
- FATTY_ACID_METABOLISM-0.181
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG454 | — | — | 0.819 |
| 2 | TCGA-85-A50M-01A-21R-A262-07 | — | cohortSQ1 | 0.799 |
| 3 | TCGA-AR-A1AL-01A-21R-A12P-07 | — | A | 0.791 |
| 4 | TCGA-AR-A24P-01A-11R-A169-07 | — | A | 0.779 |
| 5 | TCGA-68-A59I-01A-11R-A262-07 | — | cohortSQ1 | 0.769 |
| 6 | ERR2598079 | fetal | fetal | 0.768 |
| 7 | TCGA-D8-A27H-01A-11R-A16F-07 | — | E | 0.761 |
| 8 | ERR2598057 | fetal | fetal | 0.761 |
| 9 | TCGA-56-8308-01A-11R-2296-07 | — | cohortSQ2 | 0.755 |
| 10 | TCGA-P6-A5OF-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.742 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.506 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.472 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.423 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.404 | Inavolisib | — uncovered |
| HYPOXIA | 0.388 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.362 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.341 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.304 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.289 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.281 | Inavolisib | — uncovered |
| MYOGENESIS | 0.228 | Inavolisib | — uncovered |
| APOPTOSIS | 0.181 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.179 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.163 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.146 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.124 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.112 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.108 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.107 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.095 | Inavolisib | — uncovered |